ÂÜÀòÂÒÂ×

Robert Abraham, Ph.D., is Executive Vice President and Head of Cancer Biology and Target Discovery at Odyssey Therapeutics. Prior to joining Odyssey, he was the Chief Scientific Officer at Vividion Therapeutics. He is also an Adjunct Professor at the Sanford-Burnham-Prebys Medical Discovery Institute (SBPMDI) and Adjunct Professor in the Department of Pharmacology at the University of California-San Diego. Dr. Abraham received his B.S. from Bucknell University and his Ph.D. from the University of Pittsburgh, followed by post-doctoral training in both Pharmacology and Immunology at the Mayo Clinic. Dr. Abraham remained at the Mayo Clinic, where held academic positions as a Professor in the Department of Immunology and the Department of Pharmacology, and as Director of Basic Sciences in the Mayo Comprehensive Cancer Center. He then joined the faculty at the Duke University Medical Center, where he served as a Professor in the Department of Pharmacology and Cancer Biology and as the Associate Director of Translational Research in the Duke Comprehensive Cancer Center. Next, Dr. Abraham was a Professor at SBPMDI, where he founded the Signal Transduction Research Program and served as the Director of the NCI-designated SBPMDI Cancer Research Center. Dr. Abraham then transitioned from academia to industry, as Vice President of Oncology Research at Wyeth Discovery Research and later as Senior Vice President and Group Head of the Oncology R&D Group in Pfizer Worldwide Research, Development and Medical. He also was the founding Director of the Pfizer Postdoctoral Research Program. Throughout his career, Dr. Abraham has received several awards for his scientific contributions, including the Legacy Laureate Award as an outstanding alumnus of the University of Pittsburgh. He is the author of over 225 scientific publications and has served on and chaired grant review panels at the National Institutes of Health.